NEW YORK, NY / September, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data at the annual meeting of the American Society of Clinical Oncology (ASCO).
AAV‐mediated gene transfer of DNase I in the liver of mice with colorectal
cancer reduces liver metastasis and restores local innate and adaptive immune response | Publication Type | Journal article |
| Authors | |
| Abstract | Liver metastasis is the main cause of colorectal cancer (CRC)‐related death. Neutrophil extracellular traps (NETs) play important roles in CRC progression. Deoxyribonuclease I (DNase I) has been shown to alter NET function by cleaving DNA strands comprising the NET backbone. Moreover, DNase I displays high antimetastatic activity in multiple tumor models. To circumvent long‐term daily administrations of recombinant DNase I, we have developed an adeno‐associated virus (AAV) gene therapy vector to specifically express DNase I in the liver. In this study, we demonstrate AAV‐mediated DNase I liver gene transfer following a single intravenous injection suppresses the development of liver metastases in a mouse model of CRC liver metastasis. Increased levels of neutrophils and NET formation in tumors are associated with poor prognosis in many patients with advanced cancers. Neutrophil infiltration and NET formation were inhibited in tumor tissues with AAV‐DNase I treatment. This approach restored local immune responses at the tumor site by increasing the percentage of CD8+ T cells while keeping CD4+ T cells similar between AAV‐DNase I and AAV‐null treatments. Our data suggest that AAV‐mediated DNase I liver gene transfer is a safe and effective modality to inhibit metastasis and represents a novel therapeutic strategy for CRC. |
| Year of Publication | 2020 |
| Journal | Molecular Oncology |
| DOI | 10.1002/1878-0261.12787 |
NEW YORK, NY / April 08, 2020 / CLS Therapeutics, a privately held anticancer gene therapy platform company addressing a novel therapeutic target, announces presentation at the upcoming 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting that will be held from April 29 to May 2, 2019 that is planned to be held May 12 – May 15, 2020, at the Hynes Convention Center in Boston, USA.
NEW YORK, March 29, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Cancer Metabolism and Signaling” being held on May 9, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed ) encoding DNase I of the treatment of pancreatic cancer animal model.
NEW YORK, NY / September 22, 2022 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces that its project been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.